JAZZ Jazz Pharmaceuticals plc - Ordinary Shares
$256,92
Precio · Ago 19, 2026
Fundamentales a fecha de Ago 3, 2026
Rango 52S
$118–$265
94% of range
Calificación del Analista
BUY
26 analysts
Precio Objetivo
$281
+9% upside
P/E (TTM)
-29.1
ROE
—
Margen de Beneficio Neto
—
Acerca de Jazz Pharmaceuticals plc - Ordinary Shares Descripción general de la empresa de Wikipedia
Jazz Pharmaceuticals plc es una empresa biofarmacéutica global especializada en oncología y neurociencia. Se fundó en 2003 en California, Estados Unidos, y actualmente tiene su sede en Dublín, Irlanda.
Leer más
Jazz Pharmaceuticals plc (resultado de la fusión entre Jazz Pharmaceuticals, Inc. y Azur Pharma plc) es una empresa biofarmacéutica global especializada en oncología y neurociencia. Se fundó en 2003 en California, Estados Unidos, y actualmente tiene su sede en Dublín, Irlanda.
Uno de los productos más importantes de la empresa es el fármaco Xyrem (oxibato de sodio), aprobado por la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA), que es la sal sódica del neurotransmisor natural ácido γ-hidroxibutírico (GHB). En 2017, las ventas netas de Xyrem ascendieron a 1187 millones de dólares, lo que representó el 74 % de las ventas netas totales de la empresa. En 2019, Jazz obtuvo la aprobación de la FDA para comercializar Sunosi con indicaciones para el tratamiento de la somnolencia diurna excesiva (SDE) en la narcolepsia, así como de la apnea obstructiva del sueño (AOS). En 2022, se anunció que Axsome Therapeutics adquiriría Sunosi a Jazz Pharmaceuticals.
En 2007, la empresa se declaró culpable de delitos graves relacionados con la comercialización ilegal de Xyrem para usos no indicados en la ficha técnica.
La empresa también es miembro de la Asociación de Investigadores y Fabricantes Farmacéuticos de Estados Unidos (PhRMA).
Historia de la empresa y adquisiciones
2010–2019
El 18 de febrero de 2010, la FDA aceptó una solicitud de nuevo fármaco para el JZP-6 (oxibato de sodio) para el tratamiento de la fibromialgia. En diciembre del mismo año, se concedió una nueva patente para el oxibato de sodio.
El 19 de septiembre de 2011, Jazz Pharmaceuticals se fusionó con la empresa irlandesa Azur Pharma plc para formar Jazz Pharmaceuticals plc. La sede de Azur Pharma en Dublín se convirtió en la sede central de la empresa fusionada. Azur Pharma comercializaba productos farmacéuticos especializados en el sistema nervioso central (SNC) y en el ámbito de la salud femenina, y operaba en Estados Unidos desde Filadelfia.
El 26 de abril de 2012, la empresa adquirió EUSA Pharma por 650 millones de dólares (más 50 millones de dólares en pagos por hitos). En septiembre, la empresa vendió su negocio de salud femenina a Meda por 95 millones de dólares. En diciembre, la empresa inició los ensayos clínicos de L-Asparaginasa intravenosa en pacientes con leucemia linfoblástica aguda.
En enero de 2014, la empresa anunció que adquiriría la empresa desarrolladora de medicamentos para enfermedades raras Gentium SpA y su producto estrella Defibrotide por 1000 millones de dólares.
En mayo de 2016, la empresa anunció que adquiriría Alizé Pharma II por 20,5 millones de dólares. A finales de ese mismo mes, la empresa anunció su mayor adquisición hasta la fecha, con la compra de Celator Pharmaceuticals por 1500 millones de dólares. Como resultado, Jazz obtuvo los derechos del innovador tratamiento Vyxeos (daunorrubicina liposomal y citarabina) para el tratamiento de la leucemia mieloide aguda.
En agosto de 2019, la empresa anunció que adquiriría Cavion Inc. por un importe de hasta 310 millones de dólares.
2020-presente
En enero de 2021, Jazz anunció que adquiriría la empresa farmacéutica GW Pharmaceuticals, especializada en medicamentos derivados del cannabis, por 7200 millones de dólares estadounidenses. Esta adquisición añadió a la cartera de la empresa el medicamento Epidiolex (cannabidiol), desarrollado para tratar síndromes epilépticos graves.
En noviembre de 2025, Jazz Pharmaceuticals anunció los resultados positivos de su ensayo de fase III para su fármaco contra el cáncer, Ziihera, un posible tratamiento para el cáncer gastroesofágico avanzado.
Historial de adquisiciones
A continuación se muestra una ilustración de las fusiones, adquisiciones, escisiones y predecesores históricos de la empresa:
== Referencias ==
Fuente: Wikipedia, CC BY-SA 4.0 · Ver en Wikipedia ↗
JAZZ Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
Precio
$256.92
Capitalización Bursátil
—
P/E (TTM)
-29.1
BPA (TTM)
$-5.84
Ingresos (TTM)
$4.27B
Rendimiento div.
—
ROE
—
Deuda/Capital
—
Rango 52S
$118 – $265
JAZZ Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
Configure
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Ingresos y Beneficio Neto
$4.27B
2016-12-31
→
2025-12-31
BPA
$-5.84
2016-12-31
→
2025-12-31
Flujo de caja libre
—
Márgenes
—
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
Métrica
Tendencia a 5 años
JAZZ
Mediana de Pares
P/E (TTM)
-29.1
530.6
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
Métrica
Tendencia a 5 años
JAZZ
Mediana de Pares
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
Métrica
Tendencia a 5 años
JAZZ
Mediana de Pares
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
Métrica
Tendencia a 5 años
JAZZ
Mediana de Pares
Revenue YoY (Ingresos interanuales)
4.9%
—
Revenue CAGR 3Y (Ingresos CAGR 3A)
5.3%
—
Revenue CAGR 5Y (Ingresos CAGR 5A)
12.5%
—
EPS YoY (EPS interanual)
41.8%
—
Net Income YoY (Beneficio Neto interanual)
35.0%
—
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
Métrica
Tendencia a 5 años
JAZZ
Mediana de Pares
JAZZ Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
COMPRA
26 analistas
- Compra fuerte 7 26,9%
- Compra 17 65,4%
- Mantener 2 7,7%
- Venta 0 0,0%
- Venta fuerte 0 0,0%
Precio objetivo a 12 meses
20 analistas · 2026-08-15
Mediana
$285.00
Ahora
$256.92
Mín
$196.00
Máx
$315.00
Objetivo mediano
$285.00
+10,9%
Objetivo medio
$281.10
+9,4%
Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
Sorpresa Media
-0.06%
| Período | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|
| 30 de junio de 2026 | $5.71 | $6.30 | -0.59% |
| 31 de marzo de 2026 | $6.34 | $4.66 | 1.7% |
| 31 de diciembre de 2025 | $6.64 | $6.65 | -0.01% |
| 30 de septiembre de 2025 | $8.13 | $6.04 | 2.1% |
| 30 de junio de 2025 | $-8.25 | $-7.76 | -0.49% |
| 31 de marzo de 2025 | $1.68 | $4.75 | -3.1% |
Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector
| Ticker | Capitalización Bursátil | P/E | Ingresos interanuales | Margen Neto | ROE | Margen Bruto |
|---|---|---|---|---|---|---|
| JAZZ | — | -29.1 | 4.9% | — | — | — |
| GHRS | — | — | — | — | — | — |
| PRGO | $1.92B | -1.4 | -2.8% | -33.5% | -38.5% | 35.1% |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados 14
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B | $2.36B | $2.16B | $1.89B | $1.62B | $1.49B | $1.32B | $1.17B | |
| R&D Expense | · | · | · | · | · | · | $300M | $227M | $198M | $162M | $135M | $85M | |
| SG&A Expense | $1.81B | $1.39B | $1.34B | $1.42B | $1.45B | $854M | $737M | $684M | $544M | $503M | $449M | $406M | |
| Operating Expenses | $4.70B | $3.35B | $3.26B | $3.72B | $2.92B | $1.99B | $1.63B | $1.28B | $1.09B | $896M | $817M | $977M | |
| Operating Income | $-430M | $717M | $579M | $-66M | $170M | $378M | $532M | $615M | $529M | $592M | $508M | $196M | |
| Interest Income | $86M | $106M | $65M | $12M | $2M | $11M | $20M | $17M | $4M | · | · | · | |
| Other Non-op | · | · | · | · | · | · | · | · | · | · | $1M | $9M | |
| Pretax Income | $-628M | $470M | $298M | $-373M | $-113M | $275M | $454M | $529M | $441M | $532M | $436M | $152M | |
| Income Tax | $-272M | $-91M | $-120M | $-159M | $216M | $34M | $-73M | $80M | $-48M | $135M | $106M | $94M | |
| Net Income | $-356M | $560M | $415M | $-224M | $-330M | $239M | $523M | $447M | $488M | $397M | $330M | $58M | |
| EPS (Basic) | $-5.84 | $9.06 | $6.55 | $-3.58 | $-5.52 | $4.28 | $9.22 | $7.45 | $8.13 | $6.56 | $5.38 | $0.98 | |
| EPS (Diluted) | $-5.84 | $8.65 | $6.10 | $-3.58 | $-5.52 | $4.22 | $9.09 | $7.30 | $7.96 | $6.41 | $5.23 | $0.93 | |
| Shares (Basic) | 60,981,000 | 61,838,000 | 63,291,000 | 62,539,000 | 59,694,000 | 55,712,000 | 56,749,000 | 59,976,000 | 60,018,000 | 60,500,000 | 61,232,000 | 59,746,000 | |
| Shares (Diluted) | 60,981,000 | 66,007,000 | 72,066,000 | 62,539,000 | 59,694,000 | 56,517,000 | 57,550,000 | 61,221,000 | 61,317,000 | 61,870,000 | 63,036,000 | 62,614,000 |
Balance general 26
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.39B | $2.41B | $1.51B | $881M | $591M | $1.06B | $637M | $310M | $386M | $366M | $989M | $684M | |
| Receivables | $831M | $717M | $706M | $651M | $563M | $396M | $356M | $264M | $224M | $234M | $210M | $186M | |
| Inventory | $417M | $480M | $597M | $714M | $1.07B | $95M | $79M | $53M | $43M | $34M | $19M | $30M | |
| Prepaid Expense | $152M | $177M | $185M | $92M | $131M | $62M | $39M | $25M | $23M | $25M | $21M | $13M | |
| Other Current Assets | $324M | $262M | $321M | $267M | $252M | $152M | $79M | $68M | $77M | $29M | $19M | $21M | |
| Current Assets | $4.17B | $4.63B | $3.44B | $2.61B | $2.61B | $2.84B | $1.63B | $1.23B | $968M | $748M | $1.26B | $1.02B | |
| PP&E (Net) | · | · | · | · | · | $128M | $132M | $200M | $170M | $107M | $86M | $58M | |
| PP&E (Gross) | · | · | · | · | · | $196M | $187M | $250M | $211M | $140M | $109M | $74M | |
| Accum. Depreciation | · | · | · | · | · | $68M | $55M | $50M | $41M | $32M | $24M | $15M | |
| Goodwill | $1.83B | $1.72B | $1.75B | $1.69B | $1.83B | $958M | $920M | $928M | $948M | $894M | $657M | $703M | |
| Intangibles | $4.43B | $4.76B | $5.42B | $5.79B | $7.15B | $2.20B | $2.44B | $2.73B | $2.98B | $3.01B | $1.19B | $1.44B | |
| Other Non-current Assets | $99M | $114M | $67M | $55M | $41M | $26M | $48M | $43M | $16M | $14M | $9M | $16M | |
| Total Assets | $11.66B | $12.01B | $11.39B | $10.84B | $12.30B | $6.54B | $5.54B | $5.20B | $5.12B | $4.80B | $3.33B | $3.34B | |
| Accounts Payable | $122M | $78M | $103M | $91M | $100M | $27M | $46M | $41M | $24M | $22M | $22M | $25M | |
| Accrued Liabilities | $1.03B | $911M | $794M | $803M | $666M | $353M | $270M | $265M | $199M | $193M | $164M | $164M | |
| Current Liabilities | $2.24B | $1.04B | $1.54B | $933M | $809M | $654M | $364M | $345M | $294M | $257M | $227M | $217M | |
| Capital Leases | $51M | $39M | $59M | $72M | $87M | $140M | $151M | $0 | · | · | · | · | |
| Deferred Tax | $594M | $677M | $848M | $944M | $1.30B | $130M | $224M | $309M | $383M | $557M | $283M | $375M | |
| Other Non-current Liabilities | $124M | $87M | $105M | $107M | $117M | $101M | $109M | $219M | $177M | $113M | $69M | $38M | |
| Long-term Debt | $5.36B | $6.11B | $5.71B | $5.72B | $6.05B | $2.09B | $1.61B | $1.60B | $1.58B | $2.03B | $1.19B | $1.34B | |
| Common Stock | $0 | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | |
| Retained Earnings | $646M | $1.13B | $879M | $734M | $830M | $1.16B | $1.07B | $841M | $918M | $529M | $303M | $35M | |
| AOCI | $-569M | $-948M | $-842M | $-1.13B | $-400M | $-134M | $-223M | $-198M | $-141M | $-317M | $-267M | $-122M | |
| Stockholders' Equity | $4.32B | $4.09B | $3.74B | $3.09B | $3.97B | $3.66B | $3.11B | $2.76B | $2.71B | $1.88B | $1.71B | $1.37B | |
| Liabilities + Equity | $11.66B | $12.01B | $11.39B | $10.84B | $12.30B | $6.54B | $5.54B | $5.20B | $5.12B | $4.80B | $3.33B | $3.34B | |
| Shares Outstanding | 61,400,000 | 60,600,000 | 62,255,000 | 63,214,000 | 61,633,000 | 56,171,000 | 56,140,000 | 57,704,000 | 58,898,000 | 59,820,000 | 61,305,000 | 60,643,000 |
Flujo de Efectivo 12
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $42M | $33M | $30M | $30M | $27M | $19M | $15M | $15M | $13M | $12M | $10M | · | |
| Stock-based Comp | $291M | $248M | $227M | $222M | $189M | $121M | $111M | $102M | $107M | $99M | $92M | $70M | |
| Deferred Tax | $-445M | $-208M | $-260M | $-292M | $69M | $-137M | $-237M | $-89M | $-226M | $-41M | $-68M | $-49M | |
| Amort. of Intangibles | $655M | $627M | $608M | $599M | $526M | $260M | $355M | $201M | $152M | $102M | $98M | $127M | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | $2M | $2M | |
| Operating Cash Flow | $1.36B | $1.40B | $1.09B | $1.27B | $779M | $900M | $776M | $799M | $693M | $592M | $532M | $408M | |
| CapEx | $59M | $38M | $24M | $29M | $28M | $15M | $40M | $20M | $29M | $10M | $36M | $36M | |
| Investing Cash Flow | $-1.51B | $-508M | $-163M | $-446M | $-5.21B | $-1.01B | $-155M | $-394M | $-269M | $-1.75B | $-2M | $-1.07B | |
| Stock Repurchased | $125M | $311M | $270M | $54.0K | $0 | $147M | $301M | $524M | $99M | $278M | $62M | $42M | |
| Financing Cash Flow | $-873M | $21M | $-305M | $-529M | $3.97B | $528M | $-294M | $-479M | $-409M | $541M | $-214M | $711M | |
| Net Change in Cash | $-1.02B | $907M | $625M | $290M | $-466M | $420M | $328M | $-76M | $20M | $-623M | $305M | $48M | |
| Taxes Paid | $122M | $115M | $178M | · | · | · | · | · | · | · | · | · |
Tasas de Crecimiento 7
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 4.9% | 6.1% | 4.8% | 18.3% | 30.9% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 5.3% | 9.6% | 17.5% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 12.5% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | · | 41.8% | · | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | · | · | 13.1% | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | · | 35.0% | · | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | · | · | 20.2% | · | · | · | · | · | · | · | · | · |
Valoración (TTM) 5
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B | $2.36B | $2.16B | $1.89B | $1.62B | $1.49B | $1.32B | $1.17B | |
| Net Income TTM | $-356M | $560M | $415M | $-224M | $-330M | $239M | $523M | $447M | $488M | $397M | $330M | $58M | |
| P/E | -29.1 | 14.2 | 20.2 | -44.5 | -23.1 | 39.1 | 16.4 | 17.0 | 16.9 | 17.0 | 26.9 | 176.1 | |
| P / Tangible Book | · | · | · | · | · | 18.3 | · | · | · | · | · | · | |
| Earnings Yield | -3.4% | 7.0% | 5.0% | -2.2% | -4.3% | 2.6% | 6.1% | 5.9% | 5.9% | 5.9% | 3.7% | 0.57% |
Estado de resultados 13
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.21B | $1.07B | $1.20B | $1.13B | $1.05B | $898M | $1.09B | $1.05B | $1.02B | $902M | $1.01B | $972M | $957M | $893M | $972M | $941M | |
| SG&A Expense | $389M | $353M | $406M | $531M | $358M | $514M | $369M | $326M | $339M | $352M | $396M | $308M | $341M | $298M | $383M | $358M | |
| Operating Expenses | $960M | $732M | $943M | $1.07B | $1.73B | $954M | $897M | $795M | $824M | $836M | $889M | $800M | $800M | $767M | $1.24B | $916M | |
| Operating Income | $248M | $337M | $255M | $58M | $-686M | $-56M | $191M | $260M | $199M | $66M | $122M | $172M | $158M | $126M | $-263M | $25M | |
| Interest Income | $25M | $23M | $20M | $19M | $19M | $28M | $32M | $26M | $25M | $23M | $21M | $19M | $15M | $11M | $7M | $4M | |
| Pretax Income | $211M | $299M | $208M | $9M | $-736M | $-110M | $133M | $201M | $138M | $-2M | $62M | $100M | $82M | $55M | $-340M | $-60M | |
| Income Tax | $18M | $6M | $5M | $-242M | $-17M | $-18M | $-58M | $-15M | $-31M | $12M | $-33M | $-47M | $-24M | $-15M | $-100M | $-43M | |
| Net Income | $193M | $293M | $203M | $251M | $-718M | $-92M | $191M | $215M | $169M | $-15M | $94M | $147M | $104M | $69M | $-241M | $-20M | |
| EPS (Basic) | $3.05 | $4.73 | $3.28 | $4.14 | $-11.74 | $-1.52 | $3.11 | $3.50 | $2.68 | $-0.23 | $1.50 | $2.33 | $1.63 | $1.09 | $-3.86 | $-0.31 | |
| EPS (Diluted) | $2.78 | $4.43 | $3.34 | $4.08 | $-11.74 | $-1.52 | $2.97 | $3.42 | $2.49 | $-0.23 | $1.40 | $2.14 | $1.52 | $1.04 | $-3.85 | $-0.31 | |
| Shares (Basic) | 63,200,000 | 61,900,000 | -121,888,000 | 60,696,000 | 61,200,000 | 61,000,000 | -124,995,000 | 61,414,000 | 62,882,000 | 62,537,000 | -127,308,000 | 63,114,000 | 63,991,000 | 63,494,000 | -124,547,000 | 62,785,000 | |
| Shares (Diluted) | 69,400,000 | 66,100,000 | -122,798,000 | 61,606,000 | 61,200,000 | 61,000,000 | -129,329,000 | 63,174,000 | 69,625,000 | 62,537,000 | -146,538,000 | 71,293,000 | 73,540,000 | 73,771,000 | -126,584,000 | 62,785,000 | |
| EBITDA | $248M | $337M | · | $58M | $-686M | $-56M | · | $260M | $199M | $66M | · | $172M | $158M | $126M | · | $25M |
Balance general 24
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.62B | $1.84B | $1.39B | $1.33B | $1.19B | $1.86B | $2.41B | $2.22B | $1.36B | $1.44B | · | $1.34B | $1.28B | $1.17B | · | $839M | |
| Receivables | $881M | $836M | $831M | $764M | $714M | $653M | $717M | $724M | $698M | $707M | · | $628M | $610M | $624M | · | $601M | |
| Inventory | $443M | $438M | $417M | $483M | $505M | $493M | $480M | $539M | $543M | $577M | · | $612M | $657M | $675M | · | $728M | |
| Prepaid Expense | $200M | $150M | $152M | $147M | $164M | $150M | $177M | $155M | $134M | $123M | · | $110M | $107M | $73M | · | $93M | |
| Other Current Assets | $244M | $285M | $324M | $315M | $298M | $260M | $262M | $354M | $326M | $315M | · | $310M | $272M | $245M | · | $250M | |
| Current Assets | $3.97B | $4.58B | $4.17B | $3.76B | $3.35B | $4.13B | $4.63B | $4.39B | $3.68B | $3.54B | · | $3.25B | $3.01B | $2.78B | · | $2.57B | |
| Goodwill | $1.80B | $1.80B | $1.83B | $1.83B | $1.84B | $1.76B | $1.72B | $1.80B | $1.74B | $1.74B | · | $1.71B | $1.74B | $1.72B | · | $1.59B | |
| Intangibles | $4.03B | $4.20B | $4.43B | $4.57B | $4.77B | $4.72B | $4.76B | $5.14B | $5.08B | $5.24B | · | $5.42B | $5.71B | $5.76B | · | $5.57B | |
| Other Non-current Assets | $86M | $95M | $99M | $103M | $121M | $117M | $114M | $75M | $71M | $71M | · | $76M | $66M | $64M | · | $35M | |
| Total Assets | $11.08B | $11.86B | $11.66B | $11.36B | $10.94B | $11.53B | $12.01B | $12.26B | $11.36B | $11.33B | · | $11.20B | $11.26B | $11.05B | · | $10.38B | |
| Accounts Payable | $128M | $100M | $122M | $152M | $89M | $96M | $78M | $85M | $97M | $81M | · | $110M | $98M | $125M | · | $102M | |
| Accrued Liabilities | $1.03B | $1.02B | $1.03B | $1.00B | $875M | $1.06B | $911M | $859M | $801M | $827M | · | $770M | $748M | $712M | · | $668M | |
| Current Liabilities | $2.23B | $2.25B | $2.24B | $2.27B | $2.07B | $1.22B | $1.04B | $1.03B | $1.56B | $1.56B | · | $1.57B | $945M | $909M | · | $813M | |
| Capital Leases | $44M | $47M | $51M | $53M | $55M | $39M | $39M | $71M | $68M | $56M | · | $62M | $66M | $72M | · | $73M | |
| Deferred Tax | $529M | $548M | $594M | $629M | $682M | $671M | $677M | $792M | $775M | $810M | · | $841M | $911M | $932M | · | $934M | |
| Other Non-current Liabilities | $141M | $162M | $125M | $109M | $94M | $91M | $87M | $111M | $99M | $97M | · | $127M | $127M | $109M | · | $124M | |
| Long-term Debt | $4.35B | $5.35B | $5.36B | $5.36B | $5.36B | $5.37B | $6.11B | $6.11B | $5.71B | $5.71B | · | $5.72B | $5.72B | $5.72B | · | $5.73B | |
| Total Debt | $4.35B | $5.35B | · | $5.36B | $5.36B | $5.37B | · | $6.11B | $5.71B | $5.71B | · | $5.72B | $5.72B | $5.72B | · | $5.73B | |
| Common Stock | $0 | $0 | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | · | $6.0K | $6.0K | $6.0K | · | $6.0K | |
| Retained Earnings | $1.13B | $939M | $646M | $443M | $191M | $1.03B | $1.13B | $936M | $871M | $864M | · | $884M | $812M | $803M | · | $974M | |
| AOCI | $-662M | $-651M | $-569M | $-570M | $-486M | $-786M | $-948M | $-603M | $-888M | $-882M | · | $-1.04B | $-867M | $-980M | · | $-1.62B | |
| Stockholders' Equity | $4.80B | $4.53B | $4.32B | $3.96B | $3.71B | $4.17B | $4.09B | $4.17B | $3.76B | $3.70B | $3.74B | $3.49B | $3.53B | $3.34B | $3.09B | $2.75B | |
| Liabilities + Equity | $11.08B | $11.86B | $11.66B | $11.36B | $10.94B | $11.53B | $12.01B | $12.26B | $11.36B | $11.33B | · | $11.20B | $11.26B | $11.05B | · | $10.38B | |
| Shares Outstanding | 64,800,000 | 62,700,000 | 61,435,000 | 60,740,000 | 60,640,000 | 61,623,000 | 60,631,000 | 60,443,000 | 61,745,000 | 63,028,000 | 62,255,000 | 62,945,000 | · | · | 63,214,000 | · |
Flujo de Efectivo 10
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $73M | $74M | $71M | $88M | $65M | $68M | $70M | $60M | $57M | $61M | $53M | $56M | $61M | $56M | $62M | $57M | |
| Deferred Tax | $-39M | $-66M | $-63M | $-271M | $-66M | $-44M | $-2M | $-64M | $-75M | $-66M | $-36M | $-79M | $-79M | $-66M | $-145M | $-65M | |
| Amort. of Intangibles | $170M | $172M | $170M | $168M | $162M | $154M | $159M | $157M | $155M | $156M | $152M | $155M | $152M | $150M | $137M | $141M | |
| Operating Cash Flow | $416M | $408M | $363M | $475M | $89M | $430M | $399M | $399M | $331M | $267M | $167M | $307M | $297M | $321M | $342M | $418M | |
| CapEx | $18M | $20M | $17M | $15M | $13M | $14M | $13M | $11M | $7M | $7M | $10M | $4M | $6M | $4M | $9M | $-5M | |
| Investing Cash Flow | $355M | $123M | $-372M | $-328M | $-641M | $-169M | $-193M | $214M | $-257M | $-272M | $102M | $-174M | $-86M | $-5M | $-324M | $5M | |
| Stock Repurchased | · | · | $0 | $0 | · | · | $0 | $150M | · | · | $100M | $74M | · | · | $0 | $0 | |
| Financing Cash Flow | $-994M | $-78M | $75M | $-11M | $-125M | $-814M | $-8M | $246M | $-161M | $-57M | $-100M | $-78M | $-97M | $-30M | $20M | $-289M | |
| Net Change in Cash | $-224M | $452M | $66M | $136M | $-672M | $-551M | $195M | $862M | $-88M | $-63M | $171M | $53M | $114M | $286M | $42M | $128M | |
| Free Cash Flow | · | $388M | · | · | · | $416M | · | · | · | $260M | · | · | · | $317M | · | · |
Rentabilidad 7
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 20.5% | 31.5% | · | 5.1% | -65.6% | -6.2% | · | 24.7% | 19.5% | 7.3% | · | 17.7% | 16.5% | 14.1% | · | 2.6% | |
| Net Margin | 16.0% | 27.4% | · | 22.3% | -68.7% | -10.3% | · | 20.4% | 16.5% | -1.6% | · | 15.1% | 10.9% | 7.8% | · | -2.1% | |
| Pretax Margin | 17.5% | 28.0% | · | 0.80% | -70.3% | -12.2% | · | 19.0% | 13.5% | -0.18% | · | 10.2% | 8.5% | 6.2% | · | -6.4% | |
| EBITDA Margin | 20.5% | 31.5% | · | 5.1% | -65.6% | -6.2% | · | 24.7% | 19.5% | 7.3% | · | 17.7% | 16.5% | 14.1% | · | 2.6% | |
| ROA | 1.8% | 2.5% | · | 2.1% | -6.4% | -0.81% | · | 1.8% | 1.5% | -0.13% | · | 1.4% | 0.93% | 0.61% | · | -0.17% | |
| ROE | 4.5% | 6.7% | · | 6.2% | -19.2% | -2.4% | · | 5.6% | 4.6% | -0.42% | · | 4.7% | 3.1% | 2.0% | · | -0.59% | |
| ROIC | 2.5% | 3.3% | · | 17.2% | -7.4% | -0.49% | · | 2.7% | 2.6% | 5.8% | · | 2.8% | 2.2% | 1.8% | · | 0.08% |
Liquidez y Solvencia 4
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.8 | 2.0 | · | 1.7 | 1.6 | 3.4 | · | 4.3 | 2.4 | 2.3 | · | 2.1 | 3.2 | 3.1 | · | 3.2 | |
| Quick Ratio | 1.1 | 1.2 | · | 0.9 | 0.9 | 2.1 | · | 2.9 | 1.3 | 1.4 | · | 1.2 | 2.0 | 2.0 | · | 1.8 | |
| Debt / Equity | 0.9 | 1.2 | · | 1.4 | 1.4 | 1.3 | · | 1.5 | 1.5 | 1.5 | · | 1.6 | 1.6 | 1.7 | · | 2.1 | |
| LT Debt / Equity | 0.7 | 1.0 | · | 1.1 | 1.2 | 1.3 | · | 1.5 | 1.4 | 1.4 | · | 1.5 | 1.6 | 1.7 | · | 2.1 |
Eficiencia 2
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 1.5 | 1.4 | · | 1.5 | 1.5 | 1.3 | · | 1.6 | 1.6 | 1.4 | · | 1.6 | 1.6 | 1.5 | · | 1.7 |
Valoración (TTM) 13
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.45B | $4.14B | · | $4.12B | $4.02B | $3.88B | · | $3.95B | $3.86B | $3.72B | · | $3.76B | $3.72B | $3.58B | · | $3.53B | |
| Net Income TTM | $19M | $-266M | · | $-345M | $-427M | $276M | · | $516M | $405M | $306M | · | $301M | $189M | $86M | · | $-36M | |
| Market Cap | $15.61B | $11.85B | · | $8.01B | $6.44B | $7.65B | · | $6.73B | $6.59B | $7.59B | · | $8.15B | · | · | · | · | |
| Enterprise Value | $18.35B | $15.36B | · | $12.04B | $10.61B | $11.16B | · | $10.63B | $10.94B | $11.86B | · | $12.53B | · | · | · | · | |
| P/E | -535.5 | -39.8 | · | -22.9 | -14.4 | 29.8 | · | 14.2 | 18.0 | 26.9 | · | 29.5 | 44.3 | 111.7 | · | -225.9 | |
| P/S | 3.5 | 2.9 | · | 1.9 | 1.6 | 2.0 | · | 1.7 | 1.7 | 2.0 | · | 2.2 | · | · | · | · | |
| P/B | 3.3 | 2.6 | · | 2.0 | 1.7 | 1.8 | · | 1.6 | 1.8 | 2.1 | · | 2.3 | · | · | · | · | |
| P / Cash Flow | · | 29.0 | · | · | · | 17.8 | · | · | · | 28.4 | · | · | · | · | · | · | |
| P / FCF | · | 30.5 | · | · | · | 18.4 | · | · | · | 29.2 | · | · | · | · | · | · | |
| EV / EBITDA | 73.9 | 45.6 | · | 209.4 | -15.5 | -199.6 | · | 40.8 | 54.9 | 179.1 | · | 72.7 | · | · | · | · | |
| EV / FCF | · | 39.5 | · | · | · | 26.8 | · | · | · | 45.5 | · | · | · | · | · | · | |
| EV / Revenue | 4.1 | 3.7 | · | 2.9 | 2.6 | 2.9 | · | 2.7 | 2.8 | 3.2 | · | 3.3 | · | · | · | · | |
| Earnings Yield | -0.19% | -2.5% | · | -4.4% | -6.9% | 3.4% | · | 7.0% | 5.5% | 3.7% | · | 3.4% | 2.3% | 0.90% | · | -0.44% |
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
Estado de resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ingresos | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B |
| Beneficio neto | $-356M | $560M | $415M | $-224M | $-330M |
| EPS Diluido | $-5.84 | $8.65 | $6.10 | $-3.58 | $-5.52 |
Últimas noticias Noticias recientes que mencionan a esta empresa
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
📊
Elige las métricas que te importan — haz clic en el ➕ junto a cualquier fila en Fundamentales Completos arriba.
Tu selección se guarda y te sigue en todos los tickers.
Propietarios institucionales (13F) 690 declarantes · $9.8B total · A fecha de 30 de junio de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
Actividad institucional — Q2 2026 vs trimestre anterior
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 143 (+46 vs trimestre anterior) | 56 (-21 vs trimestre anterior) | 220 (+20 vs trimestre anterior) | 190 (+12 vs trimestre anterior) | +4.4M |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| FMR LLC | $846 470 147 | 3 512 762 | 8,60% | Acciones |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $731 636 247 | 3 036 213 | 7,43% | Acciones |
| VANGUARD CAPITAL MANAGEMENT LLC | $657 763 761 | 2 729 650 | 6,68% | Acciones |
| Capital World Investors | $650 043 082 | 2 697 610 | 6,60% | Acciones |
| STATE STREET CORP | $481 895 662 | 1 999 816 | 4,89% | Acciones |
| FULLER & THALER ASSET MANAGEMENT, INC. | $394 839 917 | 1 638 544 | 4,01% | Acciones |
| DIMENSIONAL FUND ADVISORS LP | $390 196 222 | 1 619 274 | 3,96% | Acciones |
| GEODE CAPITAL MANAGEMENT, LLC | $297 928 728 | 1 236 065 | 3,03% | Acciones |
| AMERIPRISE FINANCIAL INC | $260 580 996 | 1 081 421 | 2,65% | Acciones |
| CITADEL ADVISORS LLC | $242 578 716 | 1 006 676 | 2,46% | Acciones |
| Swedbank AB | $233 208 837 | 967 792 | 2,37% | Acciones |
| MILLENNIUM MANAGEMENT LLC | $184 072 164 | 763 880 | 1,87% | Acciones |
| VICTORY CAPITAL MANAGEMENT INC | $165 478 678 | 686 719 | 1,68% | Acciones |
| NORGES BANK | $158 279 458 | 656 843 | 1,61% | Acciones |
| RENAISSANCE TECHNOLOGIES LLC | $135 442 731 | 562 073 | 1,38% | Acciones |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $129 891 746 | 539 037 | 1,32% | Acciones |
| Allianz Asset Management GmbH | $122 925 785 | 510 129 | 1,25% | Acciones |
| GMT Capital Corp | $109 279 895 | 453 500 | 1,11% | Acciones |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | $105 278 106 | 436 893 | 1,07% | Acciones |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $103 893 734 | 431 148 | 1,06% | Acciones |
| TWO SIGMA INVESTMENTS, LP | $96 439 086 | 400 212 | 0,98% | Acciones |
| VANGUARD FIDUCIARY TRUST CO | $95 008 929 | 394 277 | 0,96% | Acciones |
| SYSTEMATIC FINANCIAL MANAGEMENT LP | $89 279 867 | 370 502 | 0,91% | Acciones |
| Sofinnova Investments, Inc. | $88 036 221 | 365 341 | 0,89% | Acciones |
| Polaris Capital Management, LLC | $79 270 937 | 328 966 | 0,81% | Acciones |
| AMERICAN CENTURY COMPANIES INC | $77 695 234 | 322 427 | 0,79% | Acciones |
| Bank of New York Mellon Corp | $76 961 481 | 319 382 | 0,78% | Acciones |
| GOLDENTREE ASSET MANAGEMENT LP | $70 838 675 | 294 435 | 0,72% | Acciones |
| Qube Research & Technologies Ltd | $70 056 003 | 290 725 | 0,71% | Acciones |
| FRONTIER CAPITAL MANAGEMENT CO LLC | $66 815 854 | 277 279 | 0,68% | Acciones |
| Quantinno Capital Management LP | $65 906 960 | 273 506 | 0,67% | Acciones |
| Boston Trust Walden Corp | $64 110 068 | 266 050 | 0,65% | Acciones |
| BANK OF AMERICA CORP /DE/ | $60 589 497 | 251 440 | 0,62% | Acciones |
| Tri Locum Partners LP | $53 427 868 | 221 720 | 0,54% | Acciones |
| Iron Triangle Partners LP | $49 668 900 | 292 170 | 0,50% | Acciones |
| ARGENT CAPITAL MANAGEMENT LLC | $48 211 350 | 200 072 | 0,49% | Acciones |
| GOLDMAN SACHS GROUP INC | $45 527 185 | 188 933 | 0,46% | Acciones |
| PERCEPTIVE ADVISORS LLC | $40 964 900 | 170 000 | 0,42% | Acciones |
| RAYMOND JAMES FINANCIAL INC | $39 434 259 | 163 648 | 0,40% | Acciones |
| RHUMBLINE ADVISERS | $39 282 382 | 163 018 | 0,40% | Acciones |
| Holocene Advisors, LP | $38 794 001 | 160 991 | 0,39% | Acciones |
| Saturn V Capital Management LP | $38 781 230 | 160 938 | 0,39% | Acciones |
| PFM Health Sciences, LP | $38 740 265 | 160 768 | 0,39% | Acciones |
| Retirement Systems of Alabama | $38 473 993 | 159 663 | 0,39% | Acciones |
| Woodline Partners LP | $36 165 501 | 150 083 | 0,37% | Acciones |
| LOOMIS SAYLES & CO L P | $35 355 338 | 146 721 | 0,36% | Acciones |
| Pictet Asset Management Holding SA | $35 115 175 | 147 599 | 0,36% | Acciones |
| PRINCIPAL FINANCIAL GROUP INC | $34 163 762 | 141 776 | 0,35% | Acciones |
| STIFEL FINANCIAL CORP | $33 583 066 | 139 365 | 0,34% | Acciones |
| BNP PARIBAS FINANCIAL MARKETS | $33 026 625 | 137 057 | 0,34% | Acciones |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $32 383 478 | 134 388 | 0,33% | Acciones |
| California Public Employees Retirement System | $30 759 098 | 127 647 | 0,31% | Acciones |
| WEDGE CAPITAL MANAGEMENT L L P/NC | $30 249 134 | 160 006 | 0,31% | Acciones |
| Robeco Institutional Asset Management B.V. | $28 340 967 | 117 612 | 0,29% | Acciones |
| Gotham Asset Management, LLC | $26 992 014 | 112 014 | 0,27% | Acciones |
| Aristotle Capital Management, LLC | $26 915 626 | 111 697 | 0,27% | Acciones |
| Swiss National Bank | $26 771 767 | 111 100 | 0,27% | Acciones |
| STOREBRAND ASSET MANAGEMENT AS | $26 309 828 | 109 183 | 0,27% | Acciones |
| CANADA PENSION PLAN INVESTMENT BOARD | $25 928 372 | 107 600 | 0,26% | Acciones |
| PANAGORA ASSET MANAGEMENT INC | $25 286 187 | 104 935 | 0,26% | Acciones |
| BlackRock, Inc. | $23 889 284 | 99 138 | 0,24% | Acciones |
| Perpetual Ltd | $23 733 376 | 98 491 | 0,24% | Acciones |
| WELLINGTON MANAGEMENT GROUP LLP | $23 658 917 | 98 182 | 0,24% | Acciones |
| MORGAN STANLEY | $23 519 795 | 97 604 | 0,24% | Acciones |
| Man Group plc | $23 299 389 | 96 690 | 0,24% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $22 868 053 | 94 900 | 0,23% | Opción de venta |
| ENVESTNET ASSET MANAGEMENT INC | $22 061 835 | 91 554 | 0,22% | Acciones |
| Rhenman & Partners Asset Management AB | $21 070 417 | 87 440 | 0,21% | Acciones |
| Aberdeen Group plc | $20 146 538 | 83 606 | 0,20% | Acciones |
| Amundi | $19 114 464 | 79 323 | 0,19% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $18 916 145 | 78 500 | 0,19% | Opción de compra |
| Schonfeld Strategic Advisors LLC | $18 620 232 | 77 272 | 0,19% | Acciones |
| FIRST TRUST ADVISORS LP | $18 149 860 | 75 320 | 0,18% | Acciones |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $17 765 513 | 73 725 | 0,18% | Acciones |
| LAZARD ASSET MANAGEMENT LLC | $16 768 620 | 69 588 | 0,17% | Acciones |
| Longaeva Partners L.P. | $16 576 808 | 68 792 | 0,17% | Acciones |
| Simplify Asset Management Inc. | $16 520 903 | 68 560 | 0,17% | Acciones |
| ALLIANCEBERNSTEIN L.P. | $16 497 448 | 87 265 | 0,17% | Acciones |
| Distillate Capital Partners LLC | $16 167 159 | 67 092 | 0,16% | Acciones |
| SEB Asset Management AB | $15 890 255 | 65 943 | 0,16% | Acciones |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $15 380 484 | 64 700 | 0,16% | Acciones |
| SEI INVESTMENTS CO | $14 931 224 | 61 963 | 0,15% | Acciones |
| Illinois Municipal Retirement Fund | $14 911 947 | 61 883 | 0,15% | Acciones |
| Tweedy, Browne Co LLC | $14 494 105 | 60 149 | 0,15% | Acciones |
| MARTINGALE ASSET MANAGEMENT L P | $14 335 788 | 59 492 | 0,15% | Acciones |
| DeepCurrents Investment Group LLC | $14 132 168 | 58 647 | 0,14% | Acciones |
| WORLDQUANT MILLENNIUM ADVISORS LLC | $13 348 774 | 55 396 | 0,14% | Acciones |
| VANGUARD ASSET MANAGEMENT, Ltd | $12 952 138 | 53 750 | 0,13% | Acciones |
| ExodusPoint Capital Management, LP | $12 819 845 | 53 201 | 0,13% | Acciones |
| Squarepoint Ops LLC | $12 807 074 | 53 148 | 0,13% | Acciones |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $12 034 356 | 63 657 | 0,12% | Acciones |
| ALGERT GLOBAL LLC | $11 749 697 | 48 760 | 0,12% | Acciones |
| CASTLEARK MANAGEMENT LLC | $11 306 312 | 46 920 | 0,11% | Acciones |
| CITADEL ADVISORS LLC | $11 253 299 | 46 700 | 0,11% | Opción de compra |
| RENAISSANCE GROUP LLC | $11 221 601 | 46 568 | 0,11% | Acciones |
| Nuveen, LLC | $11 184 623 | 46 415 | 0,11% | Acciones |
| PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | $10 859 795 | 45 067 | 0,11% | Acciones |
| Foundry Partners, LLC | $10 730 160 | 86 429 | 0,11% | Acciones |
| Legal & General Group Plc | $10 402 916 | 43 171 | 0,11% | Acciones |
| DEAN INVESTMENT ASSOCIATES, LLC | $10 273 274 | 42 633 | 0,10% | Acciones |
Informantes de la empresa 50 insiders · 4 directivos · 4 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| Renee D Gala | President & CEO | 30 de junio de 2026 F | 147 361 | 0 | 0 | $0 |
| Philip L Johnson | EVP & Chief Financial Officer | 30 de junio de 2026 F | 56 431 | 0 | 0 | $0 |
| Neena M Patil | EVP & Chief Legal Officer | 30 de junio de 2026 F | 48 871 | 0 | 2 | $-560 664 |
| Robert Iannone | EVP, Global Head of R&D & CMO | 30 de junio de 2026 F | 85 107 | 0 | 0 | $0 |
| Bryan C Cressey | Consejero | 9 de marzo de 2012 S | 27 631 | 0 | 0 | $0 |
| Zilkha M Nathaniel | Consejero | 10 de marzo de 2011 A | — | 0 | 0 | $0 |
| Alexander E Albert | Consejero | 15 de agosto de 2008 A | — | 0 | 0 | $0 |
| Patel Jaimin | Consejero | 15 de agosto de 2007 A | — | 0 | 0 | $0 |
| Patrick Kennedy | — | 5 de agosto de 2026 A | 8 307 | 0 | 0 | $0 |
| Samantha Pearce | — | 5 de agosto de 2026 F | 47 131 | 0 | 1 | $-1 625 977 |
| Mark Douglas Smith | — | 5 de agosto de 2026 A | 11 285 | 0 | 1 | $-266 746 |
| Jennifer E. Cook | — | 5 de agosto de 2026 A | 12 442 | 0 | 0 | $0 |
| Laura Hamill | — | 5 de agosto de 2026 A | 8 538 | 0 | 0 | $0 |
| Heather Ann Mcsharry | — | 5 de agosto de 2026 A | 20 054 | 0 | 0 | $0 |
| Seamus Mulligan | — | 5 de agosto de 2026 A | 1 184 633 | 0 | 0 | $0 |
| Rick E Winningham | — | 5 de agosto de 2026 A | 11 172 | 0 | 2 | $-1 656 873 |
| Patrick G. Enright | — | 5 de agosto de 2026 A | 22 984 | 0 | 0 | $0 |
| Bruce C Cozadd | — | 5 de agosto de 2026 A | 362 287 | 0 | 20 | $-25 646 326 |
| Ted W Love | — | 5 de agosto de 2026 A | 3 132 | 0 | 0 | $0 |
| Norbert G Riedel | — | 5 de agosto de 2026 A | 8 629 | 0 | 1 | $-655 680 |
| Kenneth W O'Keefe | — | 2 de diciembre de 2025 F | 25 811 | 0 | 0 | $0 |
| Daniel N Swisher JR | — | 3 de enero de 2019 F | 16 512 | 0 | 0 | $0 |
| Suzanne Sawochka Hooper | — | 14 de diciembre de 2018 M | 41 184 | 0 | 0 | $0 |
| Matthew P. Young | — | 23 de noviembre de 2018 S | 32 068 | 0 | 0 | $0 |
| MILLER MICHAEL PATRICK | — | 13 de noviembre de 2018 S | 24 972 | 0 | 0 | $0 |
| Paul Treacy | — | 10 de agosto de 2018 S | 17 458 | 0 | 0 | $0 |
| Elmar Schnee | — | 9 de agosto de 2018 A | 6 094 | 0 | 0 | $0 |
| Peter Gray | — | 9 de agosto de 2018 A | 8 182 | 0 | 0 | $0 |
| Catherine A. Sohn | — | 9 de agosto de 2018 A | 7 654 | 0 | 0 | $0 |
| Paul L Berns | — | 9 de agosto de 2018 A | 6 772 | 0 | 0 | $0 |
| Karen J Wilson | — | 11 de mayo de 2018 S | 15 757 | 0 | 0 | $0 |
| Karen L. Smith | — | 5 de marzo de 2018 F | 28 474 | 0 | 0 | $0 |
| Iain Mcgill | — | 5 de marzo de 2018 F | 22 048 | 0 | 0 | $0 |
| Russell J. Cox | — | 6 de marzo de 2017 F | 52 795 | 0 | 0 | $0 |
| Jeffrey K Tobias | — | 5 de marzo de 2015 F | 38 484 | 0 | 0 | $0 |
| Fintan Keegan | — | 8 de julio de 2014 M | 31 750 | 0 | 0 | $0 |
| Kathryn E Falberg | — | 5 de marzo de 2014 F | 133 387 | 0 | 0 | $0 |
| James C Momtazee | — | 13 de agosto de 2013 S | 17 315 | 0 | 0 | $0 |
| Carol A Gamble | — | 9 de marzo de 2012 S | 32 213 | 0 | 0 | $0 |
| Alan Sebulsky | — | 9 de marzo de 2012 S | 54 355 | 0 | 0 | $0 |
| Samuel D Colella | — | 11 de enero de 2012 M | 38 347 | 0 | 0 | $0 |
| Michael W Michelson | — | 11 de enero de 2012 M | 13 885 | 0 | 0 | $0 |
| Mark G. Eller | — | 13 de agosto de 2011 M | 4 151 | 0 | 0 | $0 |
| Michael A. Desjardin | — | 13 de agosto de 2011 M | 14 574 | 0 | 0 | $0 |
| Janne Lt Wissel | — | 31 de mayo de 2011 J | 48 544 | 0 | 0 | $0 |
| Joan Colligan | — | 30 de noviembre de 2010 J | 14 424 | 0 | 0 | $0 |
| Robert M Myers | — | 30 de noviembre de 2010 J | 156 898 | 0 | 0 | $0 |
| James B Tananbaum | — | 25 de agosto de 2010 A | 21 366 | 0 | 0 | $0 |
| Samuel R Saks | — | 21 de enero de 2009 A | 358 868 | 0 | 0 | $0 |
| Matthew K Fust | — | 28 de noviembre de 2008 J | 58 948 | 0 | 0 | $0 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto
Activistas y propietarios del %+ 5 6 tenencias
Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.
| Declarante | Presentado | Participación | Estado | Propósito | Presentación |
|---|---|---|---|---|---|
| Jazz Pharmaceuticals Public Limited Company, Jazz Financing I Limited, Jazz Investments II Limited, Jazz Pharmaceuticals Italy S.p.A. ×4 presentaciones | 20 de junio de 2014 | — | Presentación inicial | — | SEC |
| KKR JP LLC, KKR Millennium Fund L.P., KKR Associates Millennium L.P., KKR Millennium GP LLC, KKR Fund Holdings L.P., KKR Fund Holdings GP Limited, KKR Group Holdings L.P., KKR Group Limited, KKR & Co. L.P., KKR Management LLC, KKR JP III LLC, KKR Partners III, L.P., KKR III GP LLC, Henry R. Kravis, George R. Roberts ×3 presentaciones | 12 de marzo de 2013 | — | Presentación inicial | — | SEC |
| Longitude Capital Partners, LLC, Longitude Venture Partners, L.P., Longitude Capital Associates, L.P., Patrick G. Enright, Juliet Tammenoms Bakker ×3 presentaciones | 14 de marzo de 2012 | — | Presentación inicial | Estructura de capital | SEC |
| Longitude Capital Partners, LLC (2), Longitude Venture Partners, L.P. (2), Longitude Capital Associates, L.P. (2), Patrick G. Enright (2), Juliet Tammenoms Bakker (2) ×3 presentaciones | 30 de septiembre de 2011 | — | Presentación inicial | — | SEC |
| Azur Pharma Limited | 28 de septiembre de 2011 | — | Presentación inicial | — | SEC |
| Jazz Pharmaceuticals, Inc., KKR Millennium Fund L.P., KKR Associates Millennium L.P., KKR Millennium GP LLC, KKR Partners III, L.P., KKR III GP LLC, KKR JP LLC, KKR JP III LLC | 28 de abril de 2005 | — | Presentación inicial | M&A / venta | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Propiedad de ETFs Mantenido por 72 ETFs
El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.
| Fondo | Ponderación | Unidades | A fecha de | Fuente |
|---|---|---|---|---|
| IHE · iShares Trust | 3,55% | 224 123 SH | 8 de agosto de 2026 | Diario |
| PJP · Invesco Exchange-Traded Fund Trust | 2,75% | 54 246 SH | 8 de agosto de 2026 | Diario |
| PTH · Invesco Exchange-Traded Fund Trust | 1,88% | 18 101 SH | 8 de agosto de 2026 | Diario |
| PILL · Direxion Shares ETF Trust | 1,47% | 931 NS | 30 de abril de 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 1,10% | 3 412 SH | 8 de agosto de 2026 | Diario |
| RFG · Invesco Exchange-Traded Fund Trust | 1,01% | 14 167 SH | 8 de agosto de 2026 | Diario |
| IJK · iShares Trust | 0,86% | 367 117 SH | 8 de agosto de 2026 | Diario |
| IVOG · VANGUARD ADMIRAL FUNDS | 0,79% | 61 910 SH | 8 de agosto de 2026 | Diario |
| PDP · Invesco Exchange-Traded Fund Trust | 0,64% | 37 430 SH | 8 de agosto de 2026 | Diario |
| XJH · iShares Trust | 0,51% | 8 479 SH | 8 de agosto de 2026 | Diario |
| ISCV · iShares Trust | 0,50% | 13 756 SH | 8 de agosto de 2026 | Diario |
| LSVD · ADVISORS' INNER CIRCLE FUND | 0,50% | 14 803 NS | 30 de abril de 2026 | N-PORT |
| AVMV · AMERICAN CENTURY ETF TRUST | 0,49% | 12 809 NS | 31 de mayo de 2026 | N-PORT |
| QVMM · Invesco Exchange-Traded Fund Trust … | 0,48% | 8 322 SH | 8 de agosto de 2026 | Diario |
| IJH · iShares Trust | 0,44% | 2 164 793 SH | 8 de agosto de 2026 | Diario |
| SMMV · iShares Trust | 0,41% | 4 673 SH | 8 de agosto de 2026 | Diario |
| IVOO · VANGUARD ADMIRAL FUNDS | 0,41% | 101 353 SH | 8 de agosto de 2026 | Diario |
| VFVA · VANGUARD WELLINGTON FUND | 0,32% | 11 363 SH | 8 de agosto de 2026 | Diario |
| VBR · VANGUARD INDEX FUNDS | 0,31% | 867 777 SH | 8 de agosto de 2026 | Diario |
| AVLV · AMERICAN CENTURY ETF TRUST | 0,28% | 154 718 NS | 31 de mayo de 2026 | N-PORT |
| VFMF · VANGUARD WELLINGTON FUND | 0,28% | 8 083 SH | 8 de agosto de 2026 | Diario |
| IYH · iShares Trust | 0,25% | 35 721 SH | 8 de agosto de 2026 | Diario |
| ISCB · iShares Trust | 0,25% | 2 794 SH | 8 de agosto de 2026 | Diario |
| DFAS · Dimensional ETF Trust | 0,25% | 169 973 NS | 30 de abril de 2026 | N-PORT |
| MIDU · Direxion Shares ETF Trust | 0,24% | 1 006 NS | 30 de abril de 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,24% | 19 561 SH | 8 de agosto de 2026 | Diario |
| NUSC · Nushares ETF Trust | 0,23% | 14 796 NS | 30 de abril de 2026 | N-PORT |
| ESML · iShares Trust | 0,23% | 25 562 SH | 8 de agosto de 2026 | Diario |
| AVMC · AMERICAN CENTURY ETF TRUST | 0,20% | 3 508 NS | 31 de mayo de 2026 | N-PORT |
| SMMD · iShares Trust | 0,20% | 29 882 SH | 8 de agosto de 2026 | Diario |
| VHT · VANGUARD WORLD FUND | 0,20% | 166 548 SH | 8 de agosto de 2026 | Diario |
| RWK · Invesco Exchange-Traded Fund Trust … | 0,20% | 10 307 SH | 8 de agosto de 2026 | Diario |
| VXF · VANGUARD INDEX FUNDS | 0,17% | 719 903 SH | 8 de agosto de 2026 | Diario |
| VB · VANGUARD INDEX FUNDS | 0,17% | 1 366 973 SH | 8 de agosto de 2026 | Diario |
| DFAT · Dimensional ETF Trust | 0,17% | 113 983 NS | 30 de abril de 2026 | N-PORT |
| DFSV · Dimensional ETF Trust | 0,16% | 59 597 NS | 30 de abril de 2026 | N-PORT |
| AVUQ · AMERICAN CENTURY ETF TRUST | 0,15% | 1 679 NS | 31 de mayo de 2026 | N-PORT |
| IWS · iShares Trust | 0,15% | 89 654 SH | 8 de agosto de 2026 | Diario |
| AVIE · AMERICAN CENTURY ETF TRUST | 0,14% | 59 NS | 31 de mayo de 2026 | N-PORT |
| WSML · iShares Trust | 0,13% | 3 473 SH | 8 de agosto de 2026 | Diario |
| AVSU · AMERICAN CENTURY ETF TRUST | 0,13% | 2 492 NS | 31 de mayo de 2026 | N-PORT |
| IWR · iShares Trust | 0,11% | 243 081 SH | 8 de agosto de 2026 | Diario |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0,10% | 3 276 SH | 8 de agosto de 2026 | Diario |
| XT · iShares Trust | 0,09% | 13 696 SH | 8 de agosto de 2026 | Diario |
| AVLC · AMERICAN CENTURY ETF TRUST | 0,08% | 4 239 NS | 31 de mayo de 2026 | N-PORT |
| AVUS · AMERICAN CENTURY ETF TRUST | 0,08% | 42 911 NS | 31 de mayo de 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,07% | 2 294 NS | 31 de mayo de 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,07% | 147 813 NS | 30 de abril de 2026 | N-PORT |
| DFUV · Dimensional ETF Trust | 0,06% | 45 962 NS | 30 de abril de 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,05% | 7 081 NS | 30 de abril de 2026 | N-PORT |